Brii Biosciences

/
/
Brii Biosciences
Brii Biosciences (Stock Code: 2137.HK) is an innovative biotechnology company listed on the Main Board of the Hong Kong Stock Exchange. Operating across China and the United States, the company focuses on the research, development, and commercialization of innovative therapies in areas such as major infectious diseases and central nervous system (CNS) disorders. It is committed to addressing significant unmet global medical needs through breakthrough biologics.
Project Introduction
The project focuses on building a group-level financial accounting system aligned with international standards, enabling unified management of multiple accounting standards, multi-currency operations, and consolidated financial reporting. At the same time, it standardizes the end-to-end digital procurement process—from requisition to payment—enhancing supply chain collaboration efficiency. Through the implementation of this project, Brii Biosciences has established a solid foundation for digital operations, supporting compliant, transparent, and agile growth across its global business.
Solutions
Global Financial Management Procurement Management Bank Integration (EBP, Electronic Banking Platform) Consolidated Financial Reporting
Project Benefits
Unified Global Financial Compliance Transparent and Efficient Procurement Processes Automated Cash Reconciliation Accurate and Agile Management Decision-Making